<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62069">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01896336</url>
  </required_header>
  <id_info>
    <org_study_id>ZPDEMS1011</org_study_id>
    <nct_id>NCT01896336</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 5 mg Sublingual Zolpidem vs 10mg Oral Zolpidem in the Induction and Maintenance of Sleep in Patients With Primary Insomnia</brief_title>
  <official_title>National Study, Phase IV, Single-center, Double-blind, Randomized, Parallel, Controlled by 10 mg Oral Zolpidem, in Evaluating the Efficacy and Safety of Zolpidem 5 mg Sublingual in the Induction and Maintenance of Sleep in Patients With Primary Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Associação Fundo de Incentivo à Pesquisa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of sublingual zolpidem
      presentation 5 mg in the induction of sleep in patients with primary insomnia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  National study, phase IV, single-center, double-blind, randomized, parallel, controlled
           by zolpidem 10mg oral.

        -  Experiment duration: 93 days.

        -  05 visits (days -3, 0, 15, 45 and 90).

        -  Efficacy will be evaluated for: Sleep induction and the maintenance of sleep.

        -  Adverse events evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy will be measured by sleep induction and maintenance.</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleep induction is measured by time to sleep after administration of the investigational product.
The maintenance will be measured by the use of medication in the middle of the night and also by the elapsed time to sleep after administration of the investigational drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by the adverse events occurrences</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>5mg sublingual Zolpidem hemitartrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg oral Zolpidem hemitartrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 QD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem Hemitartrate</intervention_name>
    <description>Patz - 5mg sublingual zolpidem hemitartrate
1 QD
Stilnox - 10mg oral zolpidem hemitartrate
1 QD</description>
    <arm_group_label>5mg sublingual Zolpidem hemitartrate</arm_group_label>
    <arm_group_label>10 mg oral Zolpidem hemitartrate</arm_group_label>
    <other_name>Patz - 5mg sublingual zolpidem hemitartrate</other_name>
    <other_name>Stilnox - 10mg oral zolpidem hemitartrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged between 20 and 64 years;

          -  Diagnosis of primary insomnia according to criteria defined by DSM-IV;

          -  Difficulty in maintaining sleep and waking up until 3 am;

          -  Not having used any psychoactive drug in the last 30 days prior to their inclusion in
             the study;

          -  Signature of IC.

        Exclusion Criteria:

          -  Previous history of serious medical illness, neurological or psychiatric disorder;

          -  Allergy or hypersensitivity to zolpidem;

          -  Obstructive Sleep Apnea syndrome;

          -  Polysomnography with apnea and hypopnea index &gt;10/hour or PLM &gt;15/h;

          -  Other secondary sleep disorders;

          -  History of substance abuse or dependence;

          -  History of daily consumption of alcoholic beverages;

          -  Pregnancy, lactation or refusal to use safe contraceptive methods during the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalva R Poyares, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associacao Fundo de Incentivo a Psicofarmcologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AFIP</name>
      <address>
        <city>São Paulo</city>
        <state>Sâo Paulo</state>
        <zip>04020-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 23, 2013</lastchanged_date>
  <firstreceived_date>July 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
